{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:39:47Z","timestamp":1789000787444,"version":"build-2803163510"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To date, safe and effective strategies to prevent medically attended respiratory syncytial virus (RSV) illness across the infant population have been limited to passive immunoprophylaxis for those at highest risk. While active vaccination strategies are finally available to protect adults 60 years and older from serious RSV infection, safe and effective vaccines for use in children have yet to emerge. In contrast, passive immunization strategies designed to protect all infants against RSV has finally met with success, with 2 new strategies approved by the US Food and Drug Administration during the second half of 2023. The first RSV passive immunization strategy to gain licensure for use in all infants is an extended half-life monoclonal antibody directed against an antigenic binding site on the RSV-F prefusion protein, a conformation not known to exist until 2013. The second novel passive immunization strategy approved during 2023 that has the potential to protect much of the infant population from RSV during young infancy centers on boosting preexisting RSV immunity during pregnancy using a prefusion RSV-F vaccine. The resulting boosted humoral immune response to RSV in the mother becomes part of the transplacental antibody endowment that is actively transported across the placenta to provide protection to those babies born at or near term. This review describes how and why these advances came to fruition seemingly \u201call at once\u201d and provides insight into other passive immunization approaches that remain under development.<\/jats:p>","DOI":"10.1093\/jpids\/piae030","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T19:57:27Z","timestamp":1711655847000},"page":"S115-S124","source":"Crossref","is-referenced-by-count":19,"title":["New and Emerging Passive Immunization Strategies for the Prevention of RSV Infection During Infancy"],"prefix":"10.1093","volume":"13","author":[{"given":"Joseph B","family":"Domachowske","sequence":"first","affiliation":[{"name":"Department of Pediatrics, SUNY Upstate Medical University , Syracuse, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"key":"2024071212112207600_CIT0001","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"key":"2024071212112207600_CIT0002","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/jpids\/piz087","article-title":"Estimated burden of community-onset respiratory syncytial virus-associated hospitalizations among children aged &lt;2 years in the United States, 2014-15","volume":"9","author":"Arriola","year":"2020","journal-title":"J. Pediatric Infect Dis Soc"},{"key":"2024071212112207600_CIT0003","doi-asserted-by":"crossref","first-page":"e220527","DOI":"10.1001\/jamanetworkopen.2022.0527","article-title":"Mortality associated with influenza and respiratory syncytial virus in the US, 1999-2018","volume":"5","author":"Hansen","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2024071212112207600_CIT0004","doi-asserted-by":"crossref","first-page":"e89186","DOI":"10.1371\/journal.pone.0089186","article-title":"Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study","volume":"9","author":"Murray","year":"2014","journal-title":"PLoS One"},{"key":"2024071212112207600_CIT0005","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1186\/s12879-021-06399-8","article-title":"Economic and disease burden of RSV-associated hospitalizations in young children in France, from 2010 through 2018 [published correction appears in BMC Infect Dis. 2023 Feb 27;23(1):122]","volume":"21","author":"Demont","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2024071212112207600_CIT0006","first-page":"543","article-title":"Risk of primary infection and reinfection with respiratory syncytial virus","volume":"140","author":"Glezen","year":"1986","journal-title":"Am J Dis Child"},{"key":"2024071212112207600_CIT0007","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group","volume":"102","year":"1998","journal-title":"Pediatrics"},{"key":"2024071212112207600_CIT0008","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vaccine.2019.10.023","article-title":"Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants","volume":"38","author":"Rainisch","year":"2020","journal-title":"Vaccine"},{"key":"2024071212112207600_CIT0009","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/jiaa752","article-title":"Respiratory syncytial virus-associated hospitalization rates among US infants: a systematic review and meta-analysis","volume":"225","author":"McLaughlin","year":"2022","journal-title":"J Infect Dis"},{"key":"2024071212112207600_CIT0010","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1542\/peds.113.3.629b","article-title":"Immunoprophylaxis with RespiGam","volume":"113","author":"Meissner","year":"2004","journal-title":"Pediatrics"},{"key":"2024071212112207600_CIT0011","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/adc.2004.069948","article-title":"Palivizumab prophylaxis in haemodynamically significant congenital heart disease","volume":"90","author":"Feltes","year":"2005","journal-title":"Arch Dis Child"},{"key":"2024071212112207600_CIT0012","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3390\/pathogens12101259","article-title":"Respiratory syncytial virus vaccines: a review of the candidates and the approved vaccines","volume":"12","author":"Topalidou","year":"2023","journal-title":"Pathogens"},{"key":"2024071212112207600_CIT0013","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"2024071212112207600_CIT0014","doi-asserted-by":"crossref","first-page":"16271","DOI":"10.1038\/nmicrobiol.2016.271","article-title":"A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein","volume":"2","author":"Mousa","year":"2017","journal-title":"Nat Microbiol"},{"key":"2024071212112207600_CIT0015","doi-asserted-by":"crossref","article-title":"Phase 1 study evaluating safety, tolerability, pharmacokinetics and immunogenicity of REGN2222 in healthy adults: a new human monoclonal RSV-F antibody for RSV prevention [poster]","author":"Sivapalasingam","DOI":"10.1093\/ofid\/ofv133.628"},{"key":"2024071212112207600_CIT0016"},{"key":"2024071212112207600_CIT0017","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1038\/s41598-019-40387-y","article-title":"Emergence of new antigenic epitopes in the glycoproteins of human respiratory syncytial virus collected from a US surveillance study, 2015-17","volume":"9","author":"Lu","year":"2019","journal-title":"Sci Rep"},{"key":"2024071212112207600_CIT0018","doi-asserted-by":"crossref","first-page":"115851","DOI":"10.1016\/j.biopha.2023.115851","article-title":"Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults","volume":"169","author":"Phuah","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"2024071212112207600_CIT0019"},{"key":"2024071212112207600_CIT0020","doi-asserted-by":"crossref","first-page":"eaaj1928","DOI":"10.1126\/scitranslmed.aaj1928","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants","volume":"9","author":"Zhu","year":"2017","journal-title":"Sci Transl Med"},{"key":"2024071212112207600_CIT0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14760584.2017.1333425","article-title":"Passive and active immunization against respiratory syncytial virus for the young and old","volume":"16","author":"Villafana","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"2024071212112207600_CIT0022","doi-asserted-by":"crossref","first-page":"155","DOI":"10.58347\/tml.2023.1686a","article-title":"Two vaccines (Arexvy and Abrysvo) for prevention of RSV disease","volume":"65","year":"2023","journal-title":"Med Lett Drugs Ther"},{"key":"2024071212112207600_CIT0023","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40265-022-01829-6","article-title":"Nirsevimab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"2024071212112207600_CIT0024","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"N Engl J Med"},{"key":"2024071212112207600_CIT0025","doi-asserted-by":"crossref","first-page":"e0175792","DOI":"10.1371\/journal.pone.0175792","article-title":"Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV A and RSV B","volume":"12","author":"Hause","year":"2017","journal-title":"PLoS One"},{"key":"2024071212112207600_CIT0026","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1128\/CMR.12.2.298","article-title":"Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment","volume":"12","author":"Domachowske","year":"1999","journal-title":"Clin Microbiol Rev"},{"key":"2024071212112207600_CIT0027","doi-asserted-by":"crossref","first-page":"eaaj1879","DOI":"10.1126\/sciimmunol.aaj1879","article-title":"Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors","volume":"1","author":"Gilman","year":"2016","journal-title":"Sci Immunol"},{"key":"2024071212112207600_CIT0028","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nature12442","article-title":"Cross-neutralization of four paramyxoviruses by a human monoclonal antibody","volume":"501","author":"Corti","year":"2013","journal-title":"Nature"},{"key":"2024071212112207600_CIT0029","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1016\/j.vaccine.2018.09.056","article-title":"Antigenic and sequence variability of the human respiratory syncytial virus F glycoprotein compared to related viruses in a comprehensive dataset","volume":"36","author":"Mas","year":"2018","journal-title":"Vaccine"},{"key":"2024071212112207600_CIT0030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40121-018-0188-z","article-title":"Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children","volume":"7","author":"Sim\u00f5es","year":"2018","journal-title":"Infect Dis Ther"},{"key":"2024071212112207600_CIT0031","article-title":"REGN222, a potent neutralizing antibody","author":"Chintha"},{"key":"2024071212112207600_CIT0032","doi-asserted-by":"crossref","first-page":"e4400","DOI":"10.1093\/cid\/ciaa951","article-title":"Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants","volume":"73","author":"Sim\u00f5es","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024071212112207600_CIT0033","doi-asserted-by":"crossref","first-page":"e0175792","DOI":"10.1371\/journal.pone.0175792","article-title":"Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV\/A and RSV\/B [published correction appears in PLoS One. 2017 Jun 28;12 (6):e0180623]","volume":"12","author":"Hause","year":"2017","journal-title":"PLoS One"},{"key":"2024071212112207600_CIT0034","volume-title":"Beyfortus FDA Press Release"},{"key":"2024071212112207600_CIT0035"},{"key":"2024071212112207600_CIT0036","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose nirsevimab for prevention of RSV in preterm infants [published correction appears in N Engl J Med. 2020 Aug 13;383(7):698]","volume":"383","author":"Griffin","year":"2020","journal-title":"N Engl J Med"},{"key":"2024071212112207600_CIT0037","author":"Astra Zeneca Press Release 05 February 2018"},{"key":"2024071212112207600_CIT0038","first-page":"141","article-title":"Safety of Nirsevimab for RSV in infants with heart or lung disease or prematurity","volume":"42","author":"Domachowske","year":"2022","journal-title":"N Engl J Med"},{"key":"2024071212112207600_CIT0039","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1056\/NEJMc2214773","article-title":"Nirsevimab for prevention of RSV in term and late-preterm infants","volume":"388","author":"Muller","year":"2023","journal-title":"N Engl J Med"},{"key":"2024071212112207600_CIT0040","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N Engl J Med"},{"key":"2024071212112207600_CIT0041","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2309189","article-title":"Nirsevimab for prevention of hospitalizations due to RSV in infants","volume":"389","author":"Drysdale","year":"2023","journal-title":"N Engl J Med"},{"key":"2024071212112207600_CIT0042","doi-asserted-by":"crossref","first-page":"209","DOI":"10.15585\/mmwr.mm7309a4","article-title":"Early estimate of nirsevimab effectiveness for prevention of respiratory syncytial virus\u2013associated hospitalization among infants entering their first respiratory syncytial virus season. New Vaccine Surveillance Network, October 2023\u2013February 2024","volume":"73","author":"Moline","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024071212112207600_CIT0043","author":"Jones"},{"key":"2024071212112207600_CIT0044","doi-asserted-by":"crossref","first-page":"e2023063955","DOI":"10.1542\/peds.2023-063955","article-title":"Summer 2023 ACIP update: RSV prevention and updated recommendations on other vaccines","volume":"152","author":"O\u2019Leary","year":"2023","journal-title":"Pediatrics"},{"key":"2024071212112207600_CIT0045","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/jiaa752","article-title":"Respiratory syncytial virus-associated hospitalization rates among US infants: a systematic review and meta-analysis","volume":"225","author":"McLaughlin","year":"2022","journal-title":"J Infect Dis"},{"key":"2024071212112207600_CIT0046","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vaccine.2019.10.023","article-title":"Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants","volume":"38","author":"Rainisch","year":"2020","journal-title":"Vaccine"},{"key":"2024071212112207600_CIT0047","first-page":"S110","article-title":"Concepts of passive immunity: why passive immune protection against RSV is so appealing for the infant population","volume":"13","author":"Surydevara","year":"2024","journal-title":"J Pediatr Infect Dis Soc"},{"key":"2024071212112207600_CIT0048","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1908380","article-title":"Respiratory syncytial virus vaccination during pregnancy and effects in infants","volume":"383","author":"Madhi","year":"2020","journal-title":"N Engl J Med"},{"key":"2024071212112207600_CIT0049"},{"key":"2024071212112207600_CIT0050","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1136\/bmj.p1021","article-title":"Maternal RSV vaccine: further analysis is urged on preterm births","volume":"381","author":"Boytchev","year":"2023","journal-title":"BMJ"},{"key":"2024071212112207600_CIT0051","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"N Engl J Med"},{"key":"2024071212112207600_CIT0052"},{"key":"2024071212112207600_CIT0053"},{"key":"2024071212112207600_CIT0054","author":"Jones"},{"key":"2024071212112207600_CIT0055","author":"Hutton"},{"key":"2024071212112207600_CIT0056","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1093\/jpids\/piae017","article-title":"A review of respiratory syncytial virus epidemiology among children: linking effective prevention to vulnerable populations","volume":"13","author":"Daniels","year":"2024","journal-title":"J Pediatr Infect Dis Soc"},{"key":"2024071212112207600_CIT0057","first-page":"9","article-title":"National Perinatal Association 2024 respiratory syncytial virus (RSV) prevention clinical practice guideline: clinical presentation, prevention strategies, and social impacts in children: an evidence-based interdisciplinary collaboration","volume-title":"Neonatology Today","author":"Goldstein","year":"2024"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpids\/advance-article-pdf\/doi\/10.1093\/jpids\/piae030\/57124625\/piae030.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/13\/Supplement_2\/S115\/58521493\/piae030.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/13\/Supplement_2\/S115\/58521493\/piae030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T08:11:53Z","timestamp":1720771913000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/13\/Supplement_2\/S115\/7637867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":57,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2024,7,12]]},"published-print":{"date-parts":[[2024,7,12]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piae030","relation":{},"ISSN":["2048-7207"],"issn-type":[{"value":"2048-7207","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,7,12]]}}}